聚乙二醇干扰素-α-2a治疗乙型肝炎e抗原阳性儿科患者后乙型

StephenW

J Interferon Cytokine Res. 2019 Jul 18. doi: 10.1089/jir.2019.0042. [Epub ahead of print]
Boosting of Hepatitis B Virus-Specific T Cell Responses After Pegylated-Interferon-α-2a Therapy for Hepatitis B e Antigen-Positive Pediatric Patients.
Ning L1, Huang X1, Xu Y1, Yang G1, Yang J2, Fu Q1, Zhang Q2, Liu H2, Wu X2, Wang Z1, Luo K1.
Author information

1
    1State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, China.
2
    2Office of Prof. Kangxian Luo, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Abstract

Treatment of chronic hepatitis B with pegylated-interferon-α-2a (PegIFNα) in pediatric patients can lead to a higher rate of hepatitis B virus (HBV) surface antigen (HBsAg) loss than in adults. However, the mechanism of underlying immune response is not clear. The aim of this study was to explore innate and adaptive immunity, especially HBV-specific T cell responses in hepatitis B e antigen (HBeAg)-positive pediatric patients, who have experienced HBsAg loss. Isolated lymphocytes of 20 HBeAg-positive pediatric patients were collected every 12 weeks until treatment was stopped. The phenotype of T/natural killer (NK) cells and function of HBV-specific T cells were analyzed by flow cytometry. The frequency of CD69 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expressed on T cells and TRAIL on CD56hi NK cells in patients with HBsAg loss was remarkably higher compared with nonresponse patients. Furthermore, in vitro peptide stimulation of HBV-specific T cell responses was increased in patients with HBsAg loss when compared with week 0 and 48, and correlated with decline of viral load. The PegIFNα therapy in pediatric patients triggered T/NK cell activation and HBV-specific T cell responses, thereby contributing to successful viral control.
KEYWORDS:

HBV-specific T cell responses; HBeAg-positive CHB; IFNα; pediatric

PMID:
    31329012
DOI:
    10.1089/jir.2019.0042

StephenW

J干扰素细胞因子Res。 2019年7月18日doi：10.1089 / jir.2019.0042。 [印刷前的电子版]
聚乙二醇干扰素-α-2a治疗乙型肝炎e抗原阳性儿科患者后乙型肝炎病毒特异性T细胞应答的增强。
Ning L1，Huang X1，Xu Y1，Yang G1，Yang J2，Fu Q1，Zhang Q2，Liu H2，Wu X2，Wang Z1，Luo K1。
作者信息

1
1南方医科大学南方医院传染病与肝病科，广东省病毒性肝炎研究重点实验室器官衰竭研究国家重点实验室，广州
2
2南方医科大学南方医院罗康贤教授办公室，广州

抽象

在儿科患者中用聚乙二醇化干扰素-α-2a（PegIFNα）治疗慢性乙型肝炎可导致乙型肝炎病毒（HBV）表面抗原（HBsAg）丢失率高于成人。然而，潜在免疫反应的机制尚不清楚。本研究的目的是探索先天性和适应性免疫，尤其是乙型肝炎e抗原（HBeAg）阳性儿科患者HBV特异性T细胞应答，这些患者经历过HBsAg丢失。 20 HBeAg阳性的分离的淋巴细胞通过流式细胞术分析T /自然杀伤（NK）细胞的表型和HBV特异性T细胞的功能。 CDs和肿瘤坏死因子相关的凋亡诱导配体（TRAIL）在HBsAg损失患者的CD56hi NK细胞上表达的T细胞和TRAIL的频率显着高于无应答患者。此外，与第0周和第48周相比，HBsAg损失患者的HBV特异性T细胞应答的体外肽刺激增加，并且与病毒载量的病毒相关。儿科患者的PegIFNα治疗引发T / NK细胞活化和HBV特异性T细胞反应，从而有助于病毒控制的成功。
关键词：

HBV特异性T细胞反应; HBeAg阳性CHB; IFNα;小儿科的

结论：
31329012
DOI：
10.1089 / jir.2019.0042